APVO Aptevo Therapeutics Inc revenue, earnings and financials
For the quarter ended June 30, 2026, Aptevo Therapeutics Inc reported revenue of n/a, net income of −$6.36M and diluted EPS of −$5.31; for the fiscal year ended December 2025 revenue was n/a.
APVO annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$26.3M, net income −$26.0M (margin n/a), EPS −$87.27
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$24.6M, net income −$24.1M (margin n/a), EPS −$31460.23
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$28.9M, net income −$17.4M (margin n/a), EPS −$2316.83
- Fiscal year ended Dec 2022: revenue $3.11M, gross profit n/a, operating income −$28.6M, net income $8.03M (margin 257.8%), EPS $1.57
- Fiscal year ended Dec 2021: revenue $12.3M, gross profit n/a, operating income −$21.4M, net income −$28.5M (margin -231.5%), EPS −$6.07
APVO quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$6.36M, EPS −$5.31
- Quarter ended Mar 31, 2026: revenue n/a, net income −$6.70M, EPS −$6.41
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$5.81M, EPS $1648.06
- Quarter ended Sep 30, 2025: revenue n/a, net income −$7.55M, EPS −$2.23
- Quarter ended Jun 30, 2025: revenue n/a, net income −$6.20M, EPS −$151.29
- Quarter ended Mar 31, 2025: revenue n/a, net income −$6.41M, EPS −$1581.81
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$6.31M, EPS −$29497.20
- Quarter ended Sep 30, 2024: revenue n/a, net income −$5.10M, EPS −$357.86
- Quarter ended Jun 30, 2024: revenue n/a, net income −$5.88M, EPS −$1236.96
- Quarter ended Mar 31, 2024: revenue n/a, net income −$6.83M, EPS −$368.21
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$5.90M, EPS −$2258.10
- Quarter ended Sep 30, 2023: revenue n/a, net income −$6.33M, EPS −$22.16
- Quarter ended Jun 30, 2023: revenue n/a, net income −$7.95M, EPS −$53.95
- Quarter ended Mar 31, 2023: revenue n/a, net income $2.77M, EPS $17.38
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$4.64M, EPS −$0.96
- Quarter ended Sep 30, 2022: revenue n/a, net income −$7.64M, EPS −$1.50
- Quarter ended Jun 30, 2022: revenue n/a, net income $28.0M, EPS $5.58
- Quarter ended Mar 31, 2022: revenue $3.11M (up 28.6% year over year), net income −$7.70M, EPS −$1.55
- Quarter ended Dec 31, 2021 (from the annual report): revenue $3.67M, net income −$6.27M, EPS −$1.25
- Quarter ended Sep 30, 2021: revenue $3.10M, net income −$7.00M, EPS −$1.43
APVO cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$25.6M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$23.8M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$11.7M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$21.0M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$21.7M, share buybacks n/a
APVO balance sheet
- Jun 30, 2026: cash $9.80M, total assets $14.5M, total liabilities $8.48M, shareholders' equity $6.04M
- Mar 31, 2026: cash $14.5M, total assets $19.9M, total liabilities $8.29M, shareholders' equity $11.6M
- Dec 31, 2025: cash $21.6M, total assets $27.2M, total liabilities $9.81M, shareholders' equity $17.4M
- Sep 30, 2025: cash $21.1M, total assets $27.0M, total liabilities $9.60M, shareholders' equity $17.4M
- Jun 30, 2025: cash $9.41M, total assets $15.6M, total liabilities $9.10M, shareholders' equity $6.52M
- Mar 31, 2025: cash $2.14M, total assets $8.34M, total liabilities $9.82M, shareholders' equity −$1.47M
- Dec 31, 2024: cash $8.71M, total assets $15.6M, total liabilities $10.8M, shareholders' equity $4.76M
- Sep 30, 2024: cash $7.75M, total assets $15.1M, total liabilities $10.7M, shareholders' equity $4.42M
Is APVO profitable?
No. Aptevo Therapeutics Inc lost $26.4M over the last four quarters.
What is APVO's EPS?
Diluted earnings per share over the last four quarters were $1634.11; −$5.31 in the latest quarter.